Nocturia in men and associated comorbidities: a southeast Michigan study

Nocturia is a highly prevalent condition associated with poor quality of life and increased adverse health outcomes. Our study investigates the prevalent condition of nocturia and its profound impact on individuals’ quality of life and adverse health outcomes. We explore the correlation between nocturia and various comorbidities in a southeast Michigan population by analyzing data from 1023 participants who completed self-administered questionnaires during the 2021 Michigan Institute of Urology’s Men’s Health Event; 892 participants responded to the nocturia questionnaire. Categorizing participants based on the severity of nocturia into three groups—no nocturia, nocturia once per night, and multiple nocturia episodes per night—we employed Pearson’s Chi-square test to examine the relationship between nocturia severity and the presence of comorbidities. Our findings demonstrate significant associations between increasing episodes of nocturnal voids and the prevalence of hypertension, non-insulin-dependent diabetes and anxiety. Additionally, arthritis and colorectal polyps exhibit notable links with multiple nocturia episodes, while participants with a family history of hypertension show decreased prevalence as nocturnal voids increase, and a family history of myocardial infarction is notably associated with nocturia, particularly in the nocturia once per night group. Our research highlights the widespread impact of nocturia and its strong associations with diverse comorbidities, underscoring the importance of further investigation to comprehend the underlying mechanisms and enhance patient outcomes.

Nocturia; Comorbidities of nocturia; Quality of life; Men’s health

[1] Hashim H, Drake MJ. Basic concepts in nocturia, based on international continence society standards in nocturnal lower urinary tract function. Neurourology and Urodynamics. 2018; 37: S20–S24.

[2] Weiss JP, Bosch JLHR, Chapple CR, Bacci ED, Simeone JC, Rosenberg MT, et al. The prevalence of nocturnal polyuria in the United States: results from the epidemiology of nocturnal polyuria study. European Urology Focus. 2022; 8: 1415–1423.

[3] Olesen T, Paul J, Gramme P, Drake MJ, Vandewalle J, Everaert K. Assessment of the most impactful combination of factors associated with nocturia and to define nocturnal polyuria by multivariate modelling. Journal of Clinical Medicine. 2020; 9: 2262.

[4] Moon S, Chung HS, Yu JM, Ko KJ, Choi DK, Kwon O, et al. The association between obesity and the nocturia in the U.S. population. International Neurourology Journal. 2019; 23: 169–176.

[5] Dmochowski RR, Brucker BM. Nocturia: a nighttime condition with daytime consequences. 2019. Available at: https://www.urotoday.com/library-resources/bladder-health/111663-nocturia.html (Accessed: 10 June 2021).

[6] Tyagi S, Chancellor MB. Nocturnal polyuria and nocturia. International Urology and Nephrology. 2023; 55: 1395–1401.

[7] Madhu C, Coyne K, Hashim H, Chapple C, Milsom I, Kopp Z. Nocturia: risk factors and associated comorbidities; findings from the EpiLUTS study. International Journal of Clinical Practice. 2015; 69: 1508–1516.

[8] Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ. The economic burden of nocturia on the U.S. health care system and society: a national health and nutrition examination survey analysis. Journal of Managed Care & Specialty Pharmacy. 2019; 25: 1398–1408.

[9] Leslie SW, Sajjad H, Singh S. Nocturia. StatPearls Publishing: Treasure Island (FL). 2023.

[10] Weiss JP, Monaghan TF, Epstein MR, Lazar JM. Future considerations in nocturia and nocturnal polyuria. Urology. 2019; 133: 34–42.

[11] Fu Z, Wang F, Dang X, Zhou T. The association between diabetes and nocturia: a systematic review and meta-analysis. Frontiers in Public Health. 2022; 10: 924488.

[12] Wang CC, Jiang YH, Kuo HC. The pharmacological mechanism of diabetes mellitus-associated overactive bladder and its treatment with botulinum toxin A. Toxins. 2020; 12: 186.

[13] Funada S, Tabara Y, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, et al. Longitudinal analysis of bidirectional relationships between nocturia and depressive symptoms: the Nagahama study. Journal of Urology. 2020; 203: 984–990.

[14] Papworth E, Dawson S, Henderson EJ, Eriksson SH, Selsick H, Rees J, et al. Association of sleep disorders with nocturia: a systematic review and nominal group technique consensus on primary care assessment and treatment. European Urology Focus. 2022; 8: 42–51.

[15] Tellechea L, Zuo S, Kohn JR, Fazzari MJ, Eisenberg R, Lee J, et al. The effect of social determinants of health on overactive bladder symptom severity. Journal of Urology. 2021; 205: 1415–1420.

[16] Chellappa SL, Aeschbach D. Sleep and anxiety: from mechanisms to interventions. Sleep Medicine Reviews. 2022; 61: 101583.

[17] Yueh HZ, Yang MH, Huang JY, Wei JC. Risk of autoimmune diseases in patients with interstitial cystitis/bladder pain syndrome: a nationwide population-based study in Taiwan. Frontiers in Medicine. 2021; 8: 747098.

[18] Abushamma F, Nassar N, Najjar SO, Hijaze SM, Koni A, Zyoud SH, et al. Lower urinary tract symptoms among females with rheumatoid arthritis: a prospective cross-sectional study. International Journal of General Medicine. 2021; 14: 8427–8435.

[19] Sinimäki S, Elfeki H, Kristensen MH, Laurberg S, Emmertsen KJ. Urinary dysfunction after colorectal cancer treatment and its impact on quality of life—a national cross‐sectional study in women. Colorectal Disease. 2021; 23: 384–393.

[20] Tirdea C, Hostiuc S, Moldovan H, Scafa-Udriste A. Identification of risk genes associated with myocardial infarction-big data analysis and literature review. International Journal of Molecular Sciences. 2022; 23: 15008.